tbuckley/cabot-search huggingface dataset:
Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients
Authors: M. Maurer, J.-P. Ortonne, T. Zuberbier
Journal: British Journal of Dermatology (2008)

Journal Article Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients Get access M. Maurer, M. Maurer Allergie‐Centrum‐Charité, Department of Dermatology and Allergy, Charité– Universitätsmedizin Berlin, Charitéplatz 1, D‐10117 Berlin, Germany Correspondence: Marcus Maurer. E‐mail: marcus.maurer@charite.de Search for other works by this author on: Oxford Academic Google Scholar J.‐P. Ortonne, J.‐P. Ortonne Department of Dermatology, Hôpital de L’Archet 2, Nice, France Search for other works by this author on: Oxford Academic Google Scholar T. Zuberbier T. Zuberbier Allergie‐Centrum‐Charité, Department of Dermatology and Allergy, Charité– Universitätsmedizin Berlin, Charitéplatz 1, D‐10117 Berlin, Germany Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 160, Issue 3, 1 March 2009, Pages 633–641, https://doi.org/10.1111/j.1365-2133.2008.08920.x Published: 01 March 2009
Recurrent <i>GNAS</i> Mutations Define an Unexpected Pathway for Pancreatic Cyst Development
Authors: Jian Wu, Hanno Matthaei, Anirban Maitra, Marco Dal Molin, Laura D. Wood, James R. Eshleman, Michael Goggins, Marcia I. Canto, Richard D. Schulick, Barish H. Edil, Christopher L. Wolfgang, Alison P. Klein, Luis A. Diaz, Peter J. Allen, C. Max Schmidt, Kenneth W. Kinzler, Nickolas Papadopoulos, Ralph H. Hruban, Bert Vogelstein
Journal: Science Translational Medicine (2011)

A mutation in the gene GNAS serves as a marker for pancreatic cysts that can progress to become invasive adenocarcinomas, guiding therapy.
Climate change: our new responsibility
Authors: Fiona Godlee
Journal: BMJ (2008)

With a week to go before the NHS is 60, let’s look at some real outcomes. In the penultimate article of his series (doi: 10.1136/bmj.a385), Tony Delamothe asks how the NHS scores on patient satisfaction, mortality, and overall performance compared with other countries—surprisingly well, it seems—and Nick Timmins hears from the NHS’s medical director, former cardiothoracic surgeon Sir Bruce Keogh, about plans to record more than whether patients live or die (doi: 10.1136/bmj.39618.627951.80). Sir Bruce wants to pilot and eventually publicise patient related outcomes such as pain, mobility, and anxiety to show whether patients really feel …
Mortality from dementias and neurodegenerative disorders in people aged 15-64 in England and Wales in 1979-96
Authors: A. Majeed, P. Lehmann, L. Kirby, M. P Coleman
Journal: BMJ (1998)

There is now good evidence that the new variant of Creutzfeldt-Jakob disease first identified in 1996 is caused by exposure to bovine spongiform encephalopathy (BSE). [1]2][3] Because Creutzfeldt-Jakob disease can be difficult to diagnose, it is possible that cases of sporadic and new variant Creutzfeldt-Jakob disease have occurred that were not correctly diagnosed because postmortem or neuropathological examinations were not performed.In such cases patients could have been certified as dying from another dementia or a neurodegenerative disease.If this had occurred, mortality from Creutzfeldt-Jakob disease would have been underestimated, with a corresponding increase in mortality from other dementias and neurodegenerative disorders.We investigated whether there had been any increase in mortality from dementias and neurodegenerative disorders since 1979.
Gain-of-function mutations in the phosphatidylserine synthase 1 (PTDSS1) gene cause Lenz-Majewski syndrome
Authors: Sérgio B Sousa, Dagan Jenkins, Estelle Chanudet, Guergana Tasseva, Miho Ishida, Glenn Anderson, James Docker, Mina Ryten, Joaquim Sa, Jorge M Saraiva, Angela Barnicoat, Richard Scott, Alistair Calder, Duangrurdee Wattanasirichaigoon, Krystyna Chrzanowska, Martina Simandlová, Lionel Van Maldergem, Philip Stanier, Philip L Beales, Jean E Vance, Gudrun E Moore
Journal: Nature Genetics (2013)
Mass in Right Upper Ouadrant of the Abdomen
Authors: Kook Sang Oh
Journal: JAMA (1969)

Dr. Deborah M. Forrester: This 41-year-old Negro man was transferred from Nassau for evaluation of a mass in the right upper quadrant of the abdomen. The patient had been well until three months prior to admission when he noted intermittent pain in the right upper quadrant which radiated to the back. He had lost 11.3 kg (25 lb). Two days prior to admission, he had a temperature of 102 F (38.9 C). There was no history of jaundice, heavy alcoholic intake, parasite infestation, or change in the color of urine or stool. The physical examination was within normal limits except for a nontender, firm liver palpable four fingerbreadths below the right costal margin. No ascites or lymphadenopathy was noted. Laboratory data showed elevated sedimentation rate and abnormal liver function. The stool examination revealed no ova or parasites. <h3>Discussion</h3> Dr. Laurence L. Robbins: Dr. Janower, what is your opinion? Dr. Murray
Dermatitis due to intravesical mitomycin C: a delayed-type hypersensitivity reaction?
Authors: G.B. COLVER, J.A. INGLIS, EVA McVITTIE, M-J. SPENCER, D.A. TOLLEY, J.A.A. HUNTER
Journal: British Journal of Dermatology (1990)

Journal Article Dermatitis due to intravesical mitomycin C: a delayed‐type hypersensitivity reaction? Get access G.B. COLVER, G.B. COLVER University Department of Dermatology, The Royal Infirmary, Edinburgh Dr G.B.Colver, Department of Dermatology, The Royal Infirmary, Edinburgh EH3 9YW, U.K. Search for other works by this author on: Oxford Academic Google Scholar J.A. INGLIS, J.A. INGLIS Department of Urology, The Royal Infirmary, Edinburgh Search for other works by this author on: Oxford Academic Google Scholar EVA McVITTIE, EVA McVITTIE University Department of Dermatology, The Royal Infirmary, Edinburgh Search for other works by this author on: Oxford Academic Google Scholar M‐J. SPENCER, M‐J. SPENCER University Department of Dermatology, The Royal Infirmary, Edinburgh Search for other works by this author on: Oxford Academic Google Scholar D.A. TOLLEY, D.A. TOLLEY Department of Urology, The Royal Infirmary, Edinburgh Search for other works by this author on: Oxford Academic Google Scholar J.A.A. HUNTER J.A.A. HUNTER University Department of Dermatology, The Royal Infirmary, Edinburgh Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 122, Issue 2, 1 February 1990, Pages 217–224, https://doi.org/10.1111/j.1365-2133.1990.tb08268.x Published: 01 February 1990
Fatigue, alcohol, and serious road crashes in France: factorial study of national data
Authors: P Philip
Journal: BMJ (2001)

France has a high rate of road traffic crashes. 1 Although driver fatigue may be an important factor, 2-4 it has not been investigated in France, and no comparisons have been made with alcohol related crashes. 5We investigated the role of fatigue in serious road crashes using the French national database. 1
TCT-430 A Long Term Lumen Remodeling Analysis of a Novel Non-Drug Eluting Bioabsorbable Stent in Porcine Coronary Arteries
Authors: Carlos A. Gongora, Masahiko Shibuya, Kamal Razipoor, Chang Lee, Jenn McGregor, Yanping Cheng, Armando Tellez, Jose V. Narvaez, Edward A. Estrada, Juan Granada, Greg L. Kaluza
Journal: Journal of the American College of Cardiology (2014)
Priority setting for new technologies in medicine: qualitative case study
Authors: P. A Singer, D. K Martin, M. Giacomini, L. Purdy
Journal: BMJ (2000)

<h3>Abstract</h3> <b>Objective:</b> To describe priority setting for new technologies in medicine. <b>Design:</b> Qualitative study using case studies and grounded theory. <b>Setting:</b> Two committees advising on priorities for new technologies in cancer and cardiac care in Ontario, Canada. <b>Participants:</b> The two committees and their 26 members. <b>Main outcome measures:</b> Accounts of priority setting decision making gathered by reviewing documents, interviewing members, and observing meetings. <b>Results:</b> Six interrelated domains were identified for priority setting for new technologies in medicine: the institutions in which the decision are made, the people who make the decisions, the factors they consider, the reasons for the decisions, the process of decision making, and the appeals mechanism for challenging the decisions. <b>Conclusion:</b> These domains constitute a model of priority setting for new technologies in medicine. The next step will be to harmonise this description of how priority setting decisions are made with ethical accounts of how they should be made.
MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis
Authors: James V. Tricoli, James W. Jacobson
Journal: Cancer Research (2007)

The Cancer Diagnosis Program of the National Cancer Institute sponsored a workshop entitled “MicroRNA: Potential for Cancer Detection, Diagnosis, and Prognosis” in Rockville, Maryland on November 28 and 29, 2006. The purpose of this workshop was to bring together leaders in the microRNA (miRNA)
Triglycerides and Amputation Risk in Patients With Diabetes
Authors: Brian C. Callaghan, Eva Feldman, Jennifer Liu, Kevin Kerber, Rodica Pop-Busui, Howard Moffet, Andrew J. Karter
Journal: Diabetes Care (2011)

To determine the association between triglyceride levels and lower-extremity amputation (LEA) risk in a large diabetic cohort.This is a 10-year survey follow-up study (from 1995-2006) of 28,701 diabetic patients with a baseline triglyceride measure. All patients were fully insured members of the Kaiser Permanente Medical Care Program and responded to a survey at baseline that included information on ethnicity, socioeconomic status, education, behavioral factors, and information required to determine type of diabetes. The relationship between triglycerides and time to incident nontraumatic LEA, defined by primary hospitalization discharge or procedures, was evaluated using Cox proportional hazards models.Triglyceride level was an independent, stepwise risk factor for nontraumatic LEAs within this large diabetic cohort: triglycerides 150-199 mg/dL, hazard ratio (HR) 1.10 (95% CI 0.92-1.32); 200-499 mg/dL, 1.27 (1.10-1.47); >500 mg/dL, 1.65 (1.30-2.10) (reference <150 mg/dL).Hypertriglyceridemia is a significant risk factor for LEA in diabetic patients even after controlling for known socioeconomic, health behavioral, and clinical factors. This previously unrecognized clinical risk needs to be further investigated to determine if treatment of triglycerides can reduce amputation risk.
Temporal Arteritis and Polymyalgia Rheumatica
Authors: PER FAUCHALD
Journal: Annals of Internal Medicine (1972)

The clinical, laboratory, and histological findings in 94 patients with temporal arteritis or polymyalgia rheumatica are reported. In 61 patients biopsy specimens from the temporal artery showed arteritis; the other group of 33 patients had clinical polymyalgia rheumatica and a negative biopsy. The frequency of systemic signs was the same in both groups, and the age and sex distribution were the same. Out of 49 patients with myalgia without local findings in the temporal region 20 exhibited arteritis at biopsy. It is difficult to maintain a practical clinical distinction between the two conditions by clinical or histological criteria. The relapse rate was 26% among patients with arteritis and 18% among biopsy-negative patients; it is therefore recommended to continue corticosteroid therapy for a minimum of 2 years. By repeat biopsies during and after the treatment it was shown that histological changes in the temporal artery may persist for a long time.
Modeling metabolism: A window toward a comprehensive interpretation of networks in cancer
Authors: Osbaldo Resendis-Antonio, Carolina González-Torres, Gustavo Jaime-Muñoz, Claudia Erika Hernandez-Patiño, Carlos Felipe Salgado-Muñoz
Journal: Seminars in Cancer Biology (2014)

Given the multi-factorial nature of cancer, uncovering its metabolic alterations and evaluating their implications is a major challenge in biomedical sciences that will help in the optimal design of personalized treatments. The advance of high-throughput technologies opens an invaluable opportunity to monitor the activity at diverse biological levels and elucidate how cancer originates, evolves and responds under drug treatments. To this end, researchers are confronted with two fundamental questions: how to interpret high-throughput data and how this information can contribute to the development of personalized treatment in patients. A variety of schemes in systems biology have been suggested to characterize the phenotypic states associated with cancer by utilizing computational modeling and high-throughput data. These theoretical schemes are distinguished by the level of complexity of the biological mechanisms that they represent and by the computational approaches used to simulate them. Notably, these theoretical approaches have provided a proper framework to explore some distinctive metabolic mechanisms observed in cancer cells such as the Warburg effect. In this review, we focus on presenting a general view of some of these approaches whose application and integration will be crucial in the transition from local to global conclusions in cancer studies. We are convinced that multidisciplinary approaches are required to construct the bases of an integrative and personalized medicine, which has been and remains a fundamental task in the medicine of this century.
Republicans act to repeal health reform as they take control of House of Representatives
Authors: J. H. Tanne
Journal: BMJ (2011)

The new speaker of the US House of Representatives, the Republican John Boehner of Ohio, said that his party’s first priority was to repeal the health reform bill passed in March. 

Republicans took control of the lower house of Congress after winning a majority of seats in the November elections. They want to repeal the health bill before President Barack Obama makes his State of the Union speech at the end of this month.

Although the House may pass the repeal bill the action is symbolic, as there is almost no chance that it will be enacted into law. To become law the repeal bill would have to be passed by the Senate, which Democrats still control, and signed by President Obama, a Democrat for whom passing the reform was …
Periorbital Edema in Progressive Systemic Sclerosis
Authors: BONNIE B. DORWART
Journal: Annals of Internal Medicine (1974)

Letters1 February 1974Periorbital Edema in Progressive Systemic SclerosisBONNIE B. DORWART, M.D.BONNIE B. DORWART, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-80-2-273 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Circumscribed periorbital edema in systemic sclerosis is not mentioned in major reviews of eye findings in scleroderma and is conspicuously absent in several textbooks on ophthalmology. One text, by Walsh and Hoyt (1), notes briefly that the eyelids may be involved in localized or generalized scleroderma and that lagophthalmos (incomplete lid closure) may ensue.This case is reported to warn internists that isolated eyelid edema (Figure 1) may occur in patients with few or subtle signs of systemic scleroderma and that blindness may result unless the corneas are protected from exposure keratitis.A 43-year-old black man was...References1. WALSHHOYT FW: Clinical Neuroophthalmology, 3rd ed., vol. 2. Baltimore, The Williams & Wilkins Co., 1969, p. 1175 Google Scholar2. TURNERLIPSHUTZMILLER RWW: Esophageal dysfunction in collagen disease. Am J Med Sci 265:191-199, 1973 CrossrefMedlineGoogle Scholar3. FENNELRODNANVASQUEZ RGJ: Variability of tissue-localizing properties of serum from patients with different disease states. Lab Invest 11:24-31, 1962 Google Scholar4. RITCHIE R: Antinucleolar antibodies. N Engl J Med 282:1174-1178, 1970 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Veterans Administration Hospital Philadelphia, Pennsylvania PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySclerodermaThe ‘Connective Tissue Diseases’SclerodermaFever and Periorbital Edema: A ReviewRheumatic DiseasesOphthalmologic manifestations of rheumatic diseasesNichtrostende StähleExophthalmos associated with systemic lupus erythematosus 1 February 1974Volume 80, Issue 2Page: 273-273KeywordsBlindnessCorneaEdemaOphthalmologyScleroderma Issue Published: 1 February 1974 PDF downloadLoading ...
Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial
Authors: Amit Arjyal, Buddha Basnyat, Samir Koirala, Abhilasha Karkey, Sabina Dongol, Krishna Kumar Agrawaal, Nikki Shakya, Kabina Shrestha, Manish Sharma, Sanju Lama, Kasturi Shrestha, Nely Shrestha Khatri, Umesh Shrestha, James I Campbell, Stephen Baker, Jeremy Farrar, Marcel Wolbers, Christiane Dolecek
Journal: The Lancet Infectious Diseases (2011)

We aimed to investigate whether gatifloxacin, a new generation and affordable fluoroquinolone, is better than chloramphenicol for the treatment of uncomplicated enteric fever in children and adults.
Ventricular tachycardia. Control by intermittent, intravenous administration of lidocaine hydrochloride
Authors: J. L. Bedynek
Journal: JAMA (1966)

EXTERNAL direct-current and alternating-current countershock has proved effective in terminating ventricular tachycardia. Various medications have also been used to control this arrhythmia. This paper describes the successful use of frequent intermittent, intravenous administration of lidocaine (Xylocaine) hydrochloride to control recurrent ventricular tachycardia after the failure of other commonly available drugs. <h3>Report of a Case</h3> A 31-year-old white woman was admitted to the hospital for elective pelvic surgery. There was a history of eight normal full-term deliveries, two spontaneous abortions, and dilation and curettage had been done five times. She had had two brief episodes of palpitations, 13 and 9 months previously. Evaluation after the latter episode revealed an innocent cardiac murmur. On this admission a grade II (of VI), basal, systolic ejection murmur was heard and considered to be innocent. Results of urinalysis and serological study were normal, and a hemogram and chest roentgenogram were normal. An electrocardiogram was not
PREDICTORS OF RECURRENT RESTENOSIS AFTER TREATMENT OF DRUG-ELUTING STENT RESTENOSIS WITH PACLITAXEL-COATED BALLOON
Authors: Seiji Habara, Kazushige Kadota, Takenori Kanazawa, Tahei Ichinohe, Shunsuke Kubo, Koshi Miyake, Yusuke Hyodo, Daiji Hasegawa, Takeshi Tada, Hiroyuki Tanaka, Yasushi Fuku, Tsuyoshi Goto, Kazuaki Mitsudo
Journal: Journal of the American College of Cardiology (2014)
Adverse reactions to frusemide in hospital inpatients.
Authors: J Lowe, J Gray, D A Henry, D H Lawson
Journal: BMJ (1979)

Out of 2580 medical inpatients included in a drug-surveillance programme, 585 (22.7%) were treated with frusemide. Of these, 123 (21.0%) had a total of 177 adverse reactions. The most common were hypovolaemia (85 cases), hyperuricaemia (54), and hypokalaemia (21). Most reactions were mild, and only three patients had potentially life-threatening effects. The incidence of adverse reactions increased significantly with daily dose, occurring in 47 patients (13.5%) given up to 40 mg, 42 (26.3%) given up to 80 mg, and 34 (43.6%) given over 80 mg (P less than 0.001). There was no clear association between side effects and a raised blood urea concentration on admission, confirming that treatment with frusemide is not more hazardous in patients with renal failure. Frusemide is a safe and highly effective diuretic. Nevertheless, in view of the potential seriousness of volume depletion, dosage should probably begin at 20 rather than 40 mg daily.
Abstract 5280: PET imaging of proteolysis: Evaluation of 68Ga-DOTA and 68Ga-NODAGA chelates of an uPAR-specific peptide in a human glioblastoma xenograft model
Authors: Morten Persson, Jacob Madsen, Søren Østergaard, Michael Ploug, Andreas Kjaer
Journal: Cancer Research (2011)

Abstract Background &amp; Aim: The urokinase-type plasminogen activator receptor (uPAR) has been shown to facilitate cancer cell invasion and metastasis. uPAR is over-expressed in various cancers, including human breast, prostate and colorectal cancer, and over-expression has been shown to correlate with poor prognosis. The established correlation between uPAR expression and disease progression provides an opportunity to develop an in vivo imaging agent, which could identify cancer patients at risk. In the present study, we produced and compared two new PET tracers based on 68Ga, the chelators DOTA and NODAGA and the uPAR antagonist peptide AE105 in a human glioblastoma xenograft model using microPET/CT. Method: Both compounds were synthesized using standard Fmoc solid-phase peptide chemistry and subsequently N-terminal conjugated with either DOTA or NODAGA. The conjugated peptides were radiolabeled with 68Ga using a 68Ge/68Ga generator system, which render the production of the tracers independent of a onsite cyclotron. The compounds were evaluated in vitro by surface plasmon resonance against human uPAR and in vivo using micro-positron emission tomography in a mouse model bearing human glioblastoma U87MG xenografts. All findings were validated using uPAR ELISA on tumor tissue and uPAR immnohistochemistry on tumor slides. Results: Both compounds were labeled under mild conditions with high yield and radiochemical purity (&amp;gt;95%). Both compounds showed excellent uPAR binding (IC50 values of 10-15 nM) in vitro, which was identical to the un-conjugated peptide AE105. In vivo, they displayed different tumor uptake, with 68Ga-DOTA-AE105 and 68Ga-NODAGA-AE105 having an uptake of 0.48±0.3 and 2.58±0.02 %ID/g 0.5 hr post injection, respectively. Besides tumor uptake, high uptake in the kidneys was also observed for both compounds. Dynamic PET scans illustrated higher stability in vivo for 68Ga-NODAGA-AE105 compared to 68Ga-DOTA-AE105, thus generating the best tumor-to-background contrast. Conclusion: A new 68Ga-based PET tracer for tumor imaging of human uPAR has been developed. Based on head-to-head comparison, NODAGA seems to be the optimal chelator, giving the highest uptake in tumor tissue. The use of generator-produced 68Ga could further support translation into the clinic. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 5280. doi:10.1158/1538-7445.AM2011-5280